InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
Biotech Begins to Demonstrate Strategy to Expand NHL
InNexus Biotechnology Inc. announced the results of an extensive mouse tumor study demonstrating superiority of InNexus' DXL625 (CD20) versus Rituxan(R) in the xenograft model.
InNexus plans to submit the data for publication along with additional data from animal studies recently completed and presented at the American Association for Cancer Research (AACR) 2008 Annual Conference. The company has also launched a large scale study of DXL625 with primates, designed to evaluate toxicity and pharmokinetics, enabling the company to move the product to the FDA toward human testing.
"A study performed by an independent group investigating the survival of mice intravenously injected with B-lymphoma cells and treated subsequently with DXL625 showed a significant improvement in outcome compared to animals treated with equivalent doses of Rituxan(R), a commercially available anti-CD20 antibody," said Dr.Thomas Kindt, InNexus' Chief Scientific Officer. "Animals treated with either drug had a superior outcome when compared to those receiving inactive control (vehicle), however DXL625 had a substantial advantage over the competing antibody. We are confident that these results will translate to therapeutic advantage when DXL625 is used in human subjects."
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Bioforsk – Norwegian Institute for Agricultural and Environmental Research - Svanvik, Norway
Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian

New starting point discovered in the fight against Pseudomonas aeruginosa - Research team shows how an enzyme regulates the pathogenicity of a clinically relevant pathogen
List_of_subjects_in_Gray's_Anatomy:_IV._Myology
List_of_subjects_in_Gray's_Anatomy:_VI._The_Arteries
Cotton fibres instead of carbon nanotubes
Nanogen Issued Patent for Addressable Biologic Electrode Arrays

The more the merrier – Promiscuity in mice is a matter of free choice

A further step towards decoding smell - Researchers elucidate the role of individual brain neurons in human odor perception
Bridging that Gap Between Research and Market - Europe is well positioned to spearhead the development of a bio-based economy but must invest in demonstration activities to gain a competitive edge, says new study
